Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600327 | 0.93 | OPRL1 (0.36) | HRH3CHRM1CHRM2OPRL1OPRM1 | |
| SCHEMBL25600525 | 0.91 | OPRL1 (0.34) | HRH3CHRM1OPRL1OPRM1CHRNB2 | |
| SCHEMBL25600528 | 0.88 | HRH3 (0.37) | HRH3CHRM1CHRM2OPRL1OPRM1 | |
| SCHEMBL25605592 | 0.88 | CHRM1 (0.40) | HRH3CHRM1OPRL1OPRM1CHRM4 | |
| SCHEMBL25600338 | 0.88 | OPRL1 (0.33) | HRH3CHRM1OPRL1OPRM1CHRNB2 | |
| SCHEMBL25600526 | 0.88 | OPRL1 (0.34) | HRH3CHRM1OPRL1OPRM1CHRNB2 | |
| SCHEMBL25600527 | 0.86 | OPRL1 (0.38) | HRH3CHRM1CHRM2OPRL1OPRM1 | |
| SCHEMBL25630791 | 0.85 | CHRM1 (0.41) | HRH3CHRM1CHRM2OPRL1OPRM1 | |
| SCHEMBL25605727 | 0.84 | ALDH1A1 (0.41) | HRH3CHRM1CHRM2 | |
| SCHEMBL25600507 | 0.83 | OPRL1 (0.34) | HRH3OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885CHRM1 4634/4885CHRM2 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.